Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Do you use an LAD constraint in the setting of BID thoracic radiation for SCLC?
Related Questions
Is there a role for radiation to the primary mediastinal disease in metastatic thymic neuroendocrine carcinoma with the primary as the only residual disease after systemic therapy?
Would you offer SBRT as an alternative to surgery for an atypical carcinoid lung tumor?
Do you recommend consolidation immunotherapy after SBRT or surgery and chemo for T1-T2N0 SCLC?
Given the findings of SUNSET, demonstrating 60 Gy in 8 fractions to be a safe and effective regimen for ultracentral lesions, in what situations would you elect to use a 10 fraction hypofractionated regimen?
What is your planning approach for SBRT when the tumor abuts the great vessels such as aortic arch or SVC?
How do you treat Stage IIIC T4N3 NSCLC?
How do you counsel patients with Stage IIIA EGFR+ lung cancer regarding treatment intent with concurrent chemoRT + consolidative systemic therapy?
What is your approach to adjuvant RT or chemoRT in LS-SCLC s/p lobectomy with N1 disease?
Is there a chest wall constraint you typically use for 60 Gy in 15 fraction NSCLC treatment?
How does metaplastic thymoma histology impact your decision regarding adjuvant radiation?
